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Abstract
Background: Bv8, prokineticin-1, or endocrine gland-vascular endothelial growth factor, and
prokineticin-2 are recently isolated peptide agonists of two G protein-coupled receptors,
prokineticin receptor-1 (PROKR 1) and PROKR 2, and have been described as affecting a number
of myeloid cell functions. We evaluated the impact of Bv8 on lymphoid cells by investigating its
ability to modulate T cell cytokine balance in mouse.
Results: The production of T-helper1 cytokines (IL-2, IFN-γ and IL-1β), the T-helper 2 cytokine
IL-4, and the anti-inflammatory cytokine IL-10 by mouse splenocytes was evaluated after polyclonal
stimulation or immunisation with the keyhole limpet hemocyanin protein antigen by measuring
cytokine levels. When added in vitro to Con-A-stimulated splenocytes, Bv8 significantly increased
IL-1β and decreased IL-4 and IL-10; IL-2 and IFN-γ were not affected. Similar results were obtained
when Bv8 was administered in vivo. In KLH-immunised mice, splenocytes restimulated in vitro with
KLH and Bv8 produced significantly smaller amounts of IL-4 and IL-10. KLH-induced IL-10 and IL-
4 production was also significantly blunted in animals administered Bv8 in vivo at the time of KLH
immunisation or two weeks later. The Bv8-induced effects were lost in mice lacking the PROKR 1
gene, thus indicating that PROKR 1 is the receptor involved in the modulation of cytokines.
Conclusion: These findings indicate that Bv8/prokineticin-1 is a novel modulator of lymphoid
functions, and may be a suitable target for new immunopharmacological strategies.
Background
The small 77-amino acid protein Bv8 belongs to a novel
family of secreted proteins [1], and was given its name to
indicate its origin (the frog Bombina variegata) and molec-
ular weight (8 kD). Its orthologues have been conserved
throughout evolution from invertebrates to humans: the
mammalian orthologues are mouse Bv8 or proki-
neticin(PROK) 2 and PROK 1, and humans have Bv8-like
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proteins called prokineticin-1 (PROK 1) or endocrine
gland-vascular endothelial growth factor (EG-VEGF), and
human Bv8 or PROK 2 [2-4]. It has been shown that Bv8
and the mammal analogues have the same activity [5].
The mRNAs of the murine Bv8-like proteins PROK 1 and
2 have been detected in the brain, spinal cord, dorsal root
ganglia, gastrointestinal tract, endocrine glands, spleen
and circulating leukocytes of mice, rats and humans
[4,6,7]. Two receptors for this family of secretory proteins
(PROKR 1 and PROKR 2) have been identified in
humans, rats and mice [8,9]; they belong to the G protein-
coupled receptor family, share approximately 85% amino
acid identity, and are distributed in brain and the periph-
eral organs, including the spleen and leukocytes
[7,10,11].
The list of biological activities associated with Bv8/PROK
peptides is rapidly growing. They seem to influence com-
plex behaviours, such as feeding and drinking, and circa-
dian rhythms, and they are involved in neuronal survival,
angiogenesis, and the reproductive cycle [2,3,6,12-16]. It
has also been clearly demonstrated that Bv8 has potent
hyperalgesic activity [1,10,11,17].
It is now emerging that the immune system may be an
important target for this family of peptides. LeCouter et al.
[7] have shown that Bv8 and EG-VEGF are related to the
regulation of hematopoiesis and hematopoietic cell
mobilisation, and Dorsch et al. [18] that they are involved
in monocyte differentiation and activation.
We have recently characterised the effect of Bv8 on murine
macrophages, and shown that the protein can induce a
pro-inflammatory macrophage phenotype [19]: it stimu-
lates macrophage chemotaxis and increases the produc-
tion of the pro-inflammatory cytokines IL-1β and IL-12,
while decreasing that of IL-10. It is also well known that,
in addition to being important regulatory cells in innate
immunity, macrophages participate in the development
of T-helper (Th) cells to Th1 or Th2 [20]. IL-12 is the crit-
ical factor driving the development of Th1 cells, which are
associated with cell immune responses and tissue injury
[20-23], whereas the Th2 cells responsible for humoral
responses and allergies are stimulated by IL-4, which is
produced by Th2 lymphocytes themselves [21,22,24]. IL-
10 is a major anti-inflammatory cytokine that is produced
by monocytes/macrophages, as well as by distinct subsets
of T cells that include Th2 and several populations of the
recently identified Treg [21,25,26]. Given the effect of Bv8
on macrophages, it can be expected that the cytokine
milieu induced by Bv8 also has an impact on T cell-
derived cytokines.
For these reasons, after confirming the presence of
PROKRs on splenocyte-derived T lymphocytes, we ana-
lysed the effects of the in vitro and in vivo administration
of Bv8 on splenocyte cytokine production in mice. Th1
cytokines (IL-1β, IFN-γ and IL-2), the Th2 cytokine IL-4,
and IL-10 were evaluated after polyclonal mitogen activa-
tion, and in mice immunised with the protein antigen
keyhole limpet hemocyanin (KLH). In order to identify
the type of receptor involved, we also carried out some
experiments using cells obtained from PROKR 1 knock-
out (KO) mice.
The in vitro and in vivo activation of PROKR 1 by Bv8 sig-
nificantly decreased IL-4 and IL-10 production, without
directly affecting the Th1 cytokines, thus indicating that
the prokineticin system may compromise anti-inflamma-
tory immune responses.
Methods
Materials
Bv8 was isolated from skin secretions of the frog Bombina
variegata, and was purified to 98% as assessed by means of
HPLC [1].
Animals
Balb/CJ mice (Charles River, Calco, Italy) weighing 20–25
g were housed at 22 ± 2°C in an environment with a light/
dark cycle of 12 h, and allowed food and water ad libitum.
The characteristics of PROKR 1 KO mice have been previ-
ously described in detail [11].
Briefly, our PROKR 1 KO mice (Lexicon Genetics Inc., The
Woodlands, TX) were generated by constructing a target-
ing vector in which exon 1 of the PROKR 1 gene was
replaced with a neomycin resistance gene derived from
the LacZ/Neo vector. Lex-1 embryonic stem cells were
electroporated with the targeting vector before the cells
expressing the targeted allele were selected for the genera-
tion of the chimerae, which were then bred with C57BL/6
mice. The progeny were genotyped by means of PCR,
which permitted the amplification of the wild-type (WT)
PROKR 1 gene (5'-GGTGACTATGACATGCCCCTGG-3',
5'-CTCTCGGAAAGGGAGAGGCAAGG-3') and the neo-
mycin-resistant gene cassette, which was inserted to dis-
rupt the PROKR 1 coding region (5'-
CAGCGCATCGCCTTCTATC-3', 5'-CTCTCGGAAAGGGA-
GAGGCAAGG-3'). Genomic DNA was isolated from tail
samples by means of proteinase K (Sigma) digestion and
ethanol precipitation, and 200 ng DNA was amplified
(HotStarTaq DNA Polymerase, Qiagen) using the follow-
ing cycle parameters: 95°C for 3 min (1 cycle); 95°C for 1
min, 55°C for 1 min, 72°C for 1 min (30 cycles); and
72°C for 10 min (1 cycle). The amplified products were
resolved on 2% agarose gel.BMC Immunology 2008, 9:60 http://www.biomedcentral.com/1471-2172/9/60
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WT littermates were used as controls.
All of the animal procedures were performed in accord-
ance with the Italian and European regulations governing
the care and treatment of laboratory animals (Permit No.
94/2000A), and approved by the Institutional Review
Board of Milan University's Department of Pharmacol-
ogy.
Collection of splenocytes, and the production of 
concanavalin-A(Con-A)-induced cytokines
The spleens of the animals were aseptically removed, and
20-gauge sterile needles were used to tease the cells
through an incision made in the spleen cuticle [27,28].
The cells were adjusted in 24-well plates to 4 × 106 cells/
ml of medium (RPMI supplemented with 10% FCS, 1%
glutamine, 2% antibiotics, 0.1% 2-ME), and incubated at
37°C in 5% CO2 and 95% air in the presence or absence
of 10 μg/ml Con-A for 24 h (in the case of IL-1β, IL-2 and
IFN-γ) or 48 h (in the case of IL-10 and IL-4), which are
the times of maximum cytokine release [27,28].
In the in vitro experiments, Bv8 at concentrations ranging
from 10-7 to 10-13 M was added to the wells at the same
time as Con-A. When the PROKR 1 KO and WT mice were
used, the cells were isolated as described above, and Bv8
was added at a concentration of 10-9 M.
In the in vivo experiments, Bv8 was administered subcuta-
neously (s.c.) in the flank at a dose of 250 pmoles/kg, and
the spleens were obtained four hours later. The cells were
then incubated with or without the mitogen. The 4-hour
interval between Bv8 administration and spleen harvest-
ing was chosen on the basis of previously published data
concerning the pharmacodynamics and pharmacokinet-
ics of Bv8, which show that it modulates a number of bio-
logical functions at this time [10,29].
KLH immunisation
The mice were injected intraperitoneally (i.p.) with 100 μg
of the protein antigen KLH (Calbiochem, La Jolla, Califor-
nia) in a volume of 0.2 ml of saline; 14 days after immu-
nisation, they were decapitated and their spleens were
aseptically removed. The cells were obtained as described
above, and plated at a concentration of 7 × 106 in 24-well
plates containing a final concentration of 80 μg/ml KLH
in a total volume of 1 ml.
The presence of in vitro KLH restimulates the KLH-specific
T-lymphocyte clones previously activated by in vivo KLH.
This is a frequently used method for inducing cytokine
production by specific T-lymphocyte clones [27].
In the in vitro experiments, Bv8 (10-9 M) was added to the
wells alone or together with KLH. The plates were incu-
bated at 37°C in 5% CO2 and 95% air, and the superna-
tants were collected after 48 h (in the case of IL-2 and IFN-
γ) or 72 h (in the case of IL-10 and IL-4), which are the
times of maximum cytokine release [27]; they were then
stored frozen at -80°C for cytokine analysis. The KLH con-
centration used in vitro (80 μg/ml) was chosen on the
basis of previous experiments [27] showing that it induces
sub-maximal and easily measurable cytokine production
in such a way as to allow the detection of any stimulation
or inhibition induced by Bv8 treatment.
In the in vivo experiments, Bv8 was administered s.c. in the
flank at a dose of 250 pmoles/kg at the same time as KLH,
or 14 days after KLH immunisation and four hours before
spleen cell harvest. Bv8 was administered at these times in
order to identify when it exerts its modulatory activity dur-
ing the immunisation process: at the time of antigen rec-
ognition or at the time of final effector events. The 4-hour
interval between Bv8 administration and spleen harvest-
ing was chosen on the basis of previously published data
concerning the pharmacodynamics and pharmacokinet-
ics of Bv8, which show that it modulates a number of bio-
logical functions at this time [10,29]
The control animals were immunised with KLH and
treated with saline instead of Bv8 at the same times. The
cells were then stimulated in vitro with KLH.
The same protocols were used for the PROKR 1 KO and
WT mice.
Cytokine ELISA
The levels of IL-2, IL-4, IL-10 and IFN-γ were determined
by means of a standardised ELISA protocol (Pharmingen,
San Diego, CA). The anti-IL-2 and IL-4 (1 μg/ml) and anti-
IL-10 and IFN-γ (2 μg/ml) capture monoclonal antibodies
(mAbs) were absorbed on a polystyrene 96-well plate, and
the cytokine in the sample was bound to the antibody-
coated wells; after this, biotinylated anti-IL-10, IL-4 and
IL-2 detecting mAbs (0.5 μg/ml) and the anti-IFN-γ mAb
(1 μg/ml) were added to bind the cytokine captured by
the first antibody. After washing, avidin-peroxidase
(Sigma) was added to the wells in order to detect the bioti-
nylated detecting antibody and, finally, the 2,2'azino-
bis(3-ethylbenzthiazoline6-sulfonic acid) (ABTS, Sigma)
substrate was added. A coloured product was formed in
proportion to that measured at an optical density 405 nm.
The standard curves ranged from 15 to 2000 pg/ml for IL-
2, IL-4 and IL-10, and from 32 to 4000 pg/ml for IFN-γ.
The IL-1β levels were measured by mean of an Endogen
kit (Tema Ricerca, Bologna. Italy) in accordance with the
manufacturer's instruction. The standard curve ranged
from 15 to 1000 pg/ml.BMC Immunology 2008, 9:60 http://www.biomedcentral.com/1471-2172/9/60
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Measurement of PROKR 1 and PROKR 2 mRNA 
expression
In order to obtain purified spleen cell populations for the
real-time RT-PCR experiments, after erythrocyte lysis, the
splenocytes were appropriately stained with PE anti
CD11b for the mieloyd line, PE-anti-CD3 antibody for T
lymphocytes and FITC anti CD19 for B lymphocytes
(Miltenyi Biotec, Bologna, Italy) and the CD11b+, CD3+
CD19+ populations were purified (purity ≥ 95%) using a
BD FACSAria sorter (BD Biosciences, San Diego, CA) a
method that has been previously described in detail
[30,31]. In order to obtain sufficient cells for the RNA
extractions, spleens from 3–6 mice were used for each
staining.
Real-time quantitative PCR was performed as previously
described [11]. Briefly, total RNA was prepared from
sorted cells using the RNeasy micro Kit (Qiagen, Milan,
Italy) and quantitated using the Ribo Green RNA Quanti-
tation Kit (Invitrogen, San Giuliano Milanese, Italy)
according to manufacturer's instructions. Real-time RT-
PCR was performed using a iCycler apparatus (BIO-RAD,
Segrate, Italy) and the Quantitect SYBR one-step RT-PCR
kit (Qiagen, Milan, Italy), supplemented with 0.3 μM of
each primer pair for PROKR 1 or PROKR 2 [11] and 60 ng
of total RNA to give a final reaction volume of 25 μl. The
cycling conditions were 30 min at 50°C; 15 min at 95°C;
and then 50 cycles of 30 s at 95°C, 30 s at 52°C and 30 s
at 72°C. The individual specific PCR products were con-
firmed by means of melting curve analysis and gel electro-
phoresis, and the results were normalised to 18S RNA
expression levels within each sample [11]. The ΔCT value
was determined by subtracting the aver age 18S CT value
from the average PROKR 1, 2 and Bv8 CT in the same sam-
ple. The levels of both receptors in the different cell pop-
ulations were expressed in relation to the most expressed
value, and relatively quantified by means of the compara-
tive method: the amount of target, normalised to an
endogenous reference and relative to a calibrator (mean
of the most expressed gene ΔCT).
Statistical analysis
The results were expressed as mean values ± S.D, and ana-
lysed using one-way ANOVA followed by Bonferroni's t-
test for multiple comparisons. A P value of <0.05 was con-
sidered statistically significant.
Results
Analysis of PROKR 1 and PROKR 2 expression in 
splenocytes
The expression of PROKR 1 and PROKR 2 in most murine
immune cell types has been previously reported [18,19]
however, we used real-time RT-PCR to confirm their pres-
ence in the splenocytes used in this study (Figure 1). We
found specific transcripts for PROKR 1 and PROKR 2 in
CD11b+, CD3+ and CD19+ splenocyte-extracted RNA. The
highest PROKR expression was observed in CD11b+ cells.
In these cells we observed a predominance of PROKR 1
transcript in comparison to PROKR 2. Lower and similar
expression of both receptors was found in CD3+ and in
CD19+ cells, with a slight predominance of PROKR 2 in B
lymphocytes.
Effects of Bv8 on Con-A-stimulated cytokine production in 
vitro and in vivo
Bv8 was added to the in vitro splenocyte cultures with or
without Con-A in order to evaluate IL-1β, IL-2, IFN-γ, IL-
10 and IL-4 production. As shown in Figure 2, the sponta-
neous production of IL-1β was very low and not affected
by Bv8 which, however, significantly boosted IL-1 produc-
tion in the splenocytes stimulated by Con-A. The increase
was clear at Bv8 concentrations of 10-11, 10-9 and 10-7 M,
but the lowest concentration of 10-13 was not effective.
Panels A and B in Figure 3 show the concentrations of the
Th1 cytokines, IL-2 and IFN-γ, which were low when the
cells were cultured without mitogen, but increased after
the addition of Con-A; none of the tested Bv8 concentra-
tions had any effect. However, as shown in panel C, the in
vitro addition of Bv8 significantly reduced Con-A induced
IL-10 production at concentrations of 10-11, 10-9 and 10-7
M.
Unstimulated cells did not produce any measurable IL-4
with or without Bv8 but, when stimulated by Con-A, they
produced a substantial amount, which was significantly
PROK receptors Figure 1
PROK receptors. PROKR 1 and PROKR 2 are expressed 
in murine spleen-derived cells. RNA was extracted from 
CD11b+, CD3+ and CD19+ splenocytes and relative expres-
sion of PROKRs was evaluated by real time-RT-PCR.
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reduced by the addition of Bv8 at all of the tested concen-
trations (Fig. 3, panel D).
Figure 4 shows the effects of Bv8 on Con-A-stimulated
cytokine production in PROKR 1 KO mice and WT con-
trols. The production of cytokines by the cells obtained
from the WT controls was slightly different than that
measured in those obtained from the Balb/CJ mice (see
Figure 3), but this is not surprising as they are different
strains. Bv8 10-9 M lowered IL-10 (panel A) and IL-4 con-
centrations (panel B) in the WT controls in the same way
as in the Balb/C mice, but the fact that these effects were
completely abolished in the PROKR 1 KO mice demon-
strates their dependence on the receptor.
In order to check the in vivo ability of Bv8 to modulate
cytokine levels, it was injected s.c. at a dose of 250
pmoles/kg and, four hours later, splenocytes were
obtained and cultured with or without Con-A. The results
were similar to those observed when Bv8 was added in
vitro. As shown in Figure 5 (panel A), the levels of Con-A-
induced IL-1β were significantly increased by the admin-
istration of Bv8, whereas the production of IL-2 and IFN-
γ seemed to remain unchanged (data not shown).
The levels of unstimulated and Con-A-induced IL-10 were
significantly lower in the culture medium of the spleno-
cytes obtained from the Bv8-treated mice than in that of
the splenocytes obtained from the saline-treated animals
(Fig. 5, panel B). Significantly lower amounts of IL-4 were
also found in the Con-A-stimulated cultures of spleno-
cytes harvested from the Bv8-treated animals (Fig. 5, panel
C).
Effects of Bv8 on KLH-stimulated Th1 and Th2 cytokine 
production in vitro and in vivo
Mouse splenocytes obtained two weeks after the animals
were immunised with KLH were restimulated in vitro with
KLH 80 μg/ml, which induced the substantial production
of IL-2, IFN-γ, IL-10 and IL-4. The in vitro addition of Bv8
did not affect the production of IL-2 and IFN-γ(Fig. 6, pan-
els A and B), but significantly reduced both IL-10 and IL-
4 release (Fig. 6, panels C and D).
In a second series of experiments, Bv8 or saline was
administered in vivo to mice at the time of KLH immuni-
sation or two weeks later, four hours before the spleen
cells were harvested for in vitro restimulation with KLH.
Bv8 was administered at these times in order to identify
when it exerts its modulatory activity during the immuni-
sation process: at the time of antigen recognition or at the
time of final effector events.
The levels of IL-2 and IFN-γ produced by the KLH-stimu-
lated splenocytes obtained from the mice treated with Bv8
were no different from those measured in the control ani-
mals (data not shown), but the levels of IL-10 were signif-
icantly lower regardless of whether Bv8 was administered
at the time of KLH immunisation or four hours before in
vitro KLH restimulation (Fig. 7, panel A). Similarly, IL-4
production also decreased after Bv8 administration at
either time (Fig. 7, panel B).
In order to assess the type of PROK receptor involved in
the Bv8-induced decrease in IL-10 levels, PROKR 1 KO
mice were immunised with KLH and treated in vivo with
Bv8 at the same time (Fig. 8, panel A) or two weeks later,
four hours before the collection of splenocytes (Fig. 8,
panel B). As shown in Figure 8, and as observed in the
BalbC mice, the in vivo administration of Bv8 at either
time significantly decreased IL-10 production in the WT
animals but not in the in the PROKR 1 KO mice.
Discussion
Our results show that the newly discovered Bv8/proki-
neticin system plays a role in modulating T cell function
by reducing Th2 cytokine levels and IL-10 production,
thus indirectly switching the cells towards a Th1 and pro-
inflammatory state. We used amphibian Bv8 as it is a
potent agonist of PROKR 1 and PROKR 2, and is widely
accepted as a means of studying the effect of PROKR acti-
vation in mammals [5,11].
IL-1 production Figure 2
IL-1 production. Effect of the in vitro addition of Bv8 on IL-
1β production by mouse splenocytes in the presence or 
absence of 10 μg/ml Con-A; IL-1β levels were measured 24 
hours later. Results from one typical experiment involving 
eight mice/group. Mean values ± SD. *p < 0.05 vs CTR (Con-
A stimulated cultures without Bv8).
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We and others have previously demonstrated that the Bv8
system has a significant impact on the expression of
monocyte and macrophage cytokines by suppressing IL-
10 production and significantly increasing the production
of pro-inflammatory cytokines and IL-12 [7,18,19]. Our
present findings showing the modulation of T-lym-
phocyte cytokines indicates that the PROK system is
involved in modulating both innate and acquired immu-
nity.
The results obtained after in vitro stimulation with the pol-
yclonal mitogen Con-A, which binds to T lymphocyte
membrane glycoproteins (including TCR and CD3) but
has no stimulatory effect on other immune cell types,
indicate that Bv8 acts directly on the T lymphocyte popu-
lation in the spleen. It also modulates Con-A-induced
cytokines when administered in vivo four hours before
Con-A in vitro stimulation, a situation in which its effect
could be mediated by its activity on other cell types.
In vitro Bv8 Figure 3
In vitro Bv8. Effect of the in vitro addition of Bv8 on IL-2 (panel A), IFN-γ (panel B), IL-10 (panel C) and IL-4 production (panel 
D) by mouse splenocytes cultured in the presence or absence of 10 μg/ml Con-A for 24 h (IL-2 and IFN-γ) or 48 h (IL-10 and 
IL-4). Results from one typical experiment involving eight mice/group. Mean values ± SD. *p < 0.05 vs CTR (Con-A stimulated 
cultures without Bv8).
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PROKR 1 KO mice Figure 4
PROKR 1 KO mice. Effect of the in vitro addition of Bv8 (10-9 M) on IL-10 (panel A) and IL-4 production (panel B) by mouse 
splenocytes from WT and PROKR 1 KO mice. The cells were stimulated in vitro with Con-A for 48 h. Results from experi-
ments involving four mice/group. Mean values ± SD. *p < 0.05 vs Con-A only.
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Our KLH experiments indicate that Bv8 affects a number
of temporal steps in immune activation: the in vivo exper-
iments showed that it significantly modulates IL-4 and IL-
10 production regardless of whether it is given at the time
of KLH immunisation or four hours before in vitro KLH
restimulation. The effect of Bv8 is profound and long-last-
ing as a single administration is sufficient to shape the
response measured 14 days later. These findings suggest
that it probably acts on the early events involving naïve T
cells that take place during antigen recognition, such as
antigen presentation by dendritic cells.
However, the modulation observed four hours before in
vitro stimulation indicates that Bv8 also acts on the activa-
tion and proliferation that occur when T cells encounter
antigen in vitro. This effect is confirmed by our in vitro
experiments showing that Bv8 also decreases IL-10 and IL-
4 levels when added to splenocytes at the time of antigen
restimulation. On the whole, it seems that the effect of
Bv8 on the Th2 cytokines IL-4 and on IL-10 may not only
be due to direct interactions with T lymphocytes, but may
also be mediated by other cell types such as macrophages
[19].
However, our preliminary cytofluorimetric analysis seems
to indicate that IL-10 production is decreased mainly in
CD3+ lymphocytes [Franchi et al., unpublished results].
IL-4 is the hallmark cytokine of the Th2 phenotype, but
IL-10 is secreted by Th2 cells and a number of the recently
identified Treg populations that play a crucial role in lim-
iting inflammation [25,26]. It can be hypothesized that
Bv8 affects the induction of specific IL-10-producing T
cells, but future detailed studies are needed to characterise
In vivo Bv8 Figure 5
In vivo Bv8. Effect of the in vivo administration of Bv8 250 pmoles/kg on the splenocyte production of IL-1β, IL-10 and IL-4. 
The splenocytes were obtained 4 h after Bv8 treatment and stimulated in vitro in the presence or absence of 10 μg/ml Con-A 
for 24 h (IL-1) or 48 h (IL-10 and IL-4). Results from one typical experiment involving eight mice/group. Mean values ± SD. *p 
< 0.05 vs saline-treated animals.
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the T lymphocytes targeted by Bv8 to reduce IL-10 produc-
tion.
Two receptors of the family of secretory proteins (PROKR
1 and PROKR 2) have been identified in humans, rats and
mice [8,9]. They belong to the G protein-coupled receptor
family, share approximately 85% amino acid identity, and
are distributed in brain and the peripheral organs, includ-
ing the spleen, and leukocytes [7-11,18,19].
In particular, Dorsch et al. [18] have demonstrated the
presence of both receptors on T and B lymphocytes, as
well as on macrophages purified from murine spleen, and
we have also shown [19] the high expression of PROKR 1
in murine peritoneal macrophages. We now confirm that
specific transcripts for both receptors are present in the
purified spleen-derived macrophages, T and B lym-
phocytes. Both PROKR 1 and 2 are more highly expressed
in CD11b+ cells than in T and B lymphocytes; moreover
in this cell type a predominance of PROKR 1 transcripts
over PROKR 2 is found. This last observation is consistent
with our previous results in peritoneal macrophages [19],
although does not completely agree with other data show-
ing a relative prevalence of PROKR 2 [18]. Consistently
with the data reported by Dorsch et al., [18], equal PROKR
1 and PROKR 2 expression appears to be present in T lym-
phocytes, while PROKR 2 is slightly more abundant in B
cells. A recent review [32] on the presence of PROKRs in
the immune cells, has suggested that the distribution of
the two receptors can differ between human and murine
cells and that further analysis are needed. As PROKRs are
present on all cell types present in the spleen, it is likely
KLH immunisation + in vitro Bv8 Figure 6
KLH immunisation + in vitro Bv8. Effect of in vitro addition of Bv8 (10-9 M) on IL-2 (panel A), IFN-γ (panel B), IL-10 (panel 
C) and IL-4 production (panel D) by splenocytes of mice immunised with KLH. Two weeks after immunisation, the splenocytes 
were cultured in the presence or absence of 80 μg/ml KLH for 48 h (IL-2 and IFN-γ) or 72 h (IL-10 and IL-4). Results from one 
typical experiment involving eight mice/group. Mean values ± SD. *p < 0.05 vs KLH-stimulated cultures without Bv8.
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KLH immunisation + in vivo Bv8 Figure 7
KLH immunisation + in vivo Bv8. Effect of the in vivo administration of Bv8 250 pmoles/kg on the production of IL-10 
(panel A) and IL-4 (panel B) by splenocytes of mice immunised with KLH. Two weeks after immunisation, the splenocytes were 
cultured in the presence or absence of 80 μg/ml KLH for 72 h. Bv8 was administered at the time of immunisation (KLH + Bv8) 
or 4 h before splenocyte collection two weeks later (KLH +Bv4 h). Results from one typical experiment involving eight mice/
group. Mean values ± SD. *p < 0.05 vs corresponding saline-treated animals.
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KLH immunisation in PROKR 1 KO mice Figure 8
KLH immunisation in PROKR 1 KO mice. Effect of the in vivo administration of Bv8 250 pmoles/kg on the production of 
IL-10 by splenocytes of WT and PROKR 1 KO mice immunised with KLH. Two weeks after immunisation, the splenocytes 
were cultured in the presence or absence of 80 μg/ml for 72 h. Bv8 was administered at the time of immunisation (panel A) or 
4 h before splenocyte collection two weeks later (panel B). Results from typical experiments involving four mice/group. Mean 
values ± SD. *p < 0.05 vs saline-treated animals of the same strain.
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that Bv8 regulates cytokine production binding to multi-
ple immune cells. However, the loss of effect of Bv8
observed in our PROKR 1 KO mice suggests that PROKR 1
is the main receptor involved in modulating immune
responses, which is in line with our previous findings
indicating that it is exclusively responsible for mediating
the modulation of macrophage cytokine production [19].
Moreover, considering the high expression of this receptor
on cells of the myeloid lineage, it can be hypothesized
that the Bv8 immune effects are due to the activation of
this population, rather than to a direct effect on T lym-
phocytes. This aspect will be evaluated in future work.
As immune cells produce PROK, possess functional recep-
tors and respond to Bv8, prokineticins may play a role as
autocrine/paracrine regulators of immune responses.
Bv8 is highly expressed in mouse and human immune
cells, and has been reported in mouse and human mono-
cytes, macrophages, granulocytes, spleen and bone mar-
row [7,18,19]. We also confirm that purified CD3
lymphocytes also express Bv8 mRNA (Franchi et al,
unpublished data). Furthermore, prokineticins are signif-
icantly overexpressed in inflamed tissues and, in line with
this, it has been found that Bv8, PROK and their receptors
are all involved in inflammatory processes and mediate
inflammatory pain [10,11]. It has very recently been
shown that the implantation of tumour cells in mice
upregulates Bv8 in serum, bone marrow and spleen mye-
loid cells, and that G-CSF is a positive major regulator of
Bv8 expression [5]. It can be hypothesised that the Bv8
produced by myeloid cells under these different condi-
tions acts as a cytokine on T cell functions.
A disrupted balance of pro- and anti-inflammatory
cytokine production, and alterations in the induction of
the different T cell populations, are involved in the devel-
opment of various immune diseases [25,33,34], and so
the effects of Bv8 on different types of T cell may play a
broad pathophysiological role. Moreover, recent studies
have begun to identify some peptide antagonists of
PROKR 1 receptors [35,36] that may offer a novel
approach to the development of drugs designed to modu-
late immune/inflammatory responses.
Conclusion
Various activities have been associated with Bv8 signal-
ling, and this family of proteins is emerging as an impor-
tant new modulator of immune responses. We show that
Bv8 plays a specialised role in modulating T cell cytokine
production as it significantly reduces IL-4 and IL-10.
Given the important role that both cytokines play in lim-
iting inflammation, it can be suggested that the Bv8/
PROK system plays a general pro-inflammatory role,
which means that Bv8 or its receptors may represent new
therapeutic targets.
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